Latest & greatest articles for insomnia

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on insomnia or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on insomnia and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for insomnia

1. EAN/ERS/ESO/ESRS statement on the impact of sleep disorders on risk and outcome of stroke

as overall health status. The most common SWDs are sleep-disordered breathing (SDB), insomnia and sleep-related move- ment disorders, such as restless limb syndrome (RLS) and periodic limb movements in sleep (PLMS) [3]. Sleep-disordered breathing is highly prevalent and may present as obstructive or central apnoeas and hypopnoeas, and/or hypoventilation. The obstructive form is most common and recent population-based epidemiological studies have reported a prevalence of obstructive apnoeas and hypopnoeas (...) (for details of the process refer to the Supporting information) [37–39]. The task force developed a document focusing on the following main topics: 1) Sleepwake disorders, such as sleep-related breathing disorders, insomnia and RLS/PLMS disorder, as risk factors of stroke 2) E?ect of treatment of SWDs on prevention of stroke 3) Frequency of SWDs as a consequence of stroke 4) Outcome of sleep-related breathing disorders and possible treatment e?ects of SWDs in patients with acute stroke The task force did

2020 European Academy of Neurology

2. Helping Canadian Health Care Providers to Optimize Sleep Disordered Breathing Management for their Patients during the COVID-19 Pandemic

, Dalhousie University, Halifax, Nova Scotia, Canada; j Department of Pediatrics, Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada; k Division of Respiratory, Critical Care and Sleep Medicine, University of Saskatchewan, Saskatoon, Saskatchewan, Canada; l School of Health Sciences, Dalhousie University, Halifax, Nova Scotia, Canada. Version 1.0 – April 16, 2020 Sleep Disordered Breathing (SDB) is a common chronic disorder and encompasses a range of diseases including obstructive (...) Helping Canadian Health Care Providers to Optimize Sleep Disordered Breathing Management for their Patients during the COVID-19 Pandemic 1 ‘In Press’. Submitted for publication in the CJRCCSM on April 16, 2020. POSITION STATEMENT FROM THE CANADIAN THORACIC SOCIETY (CTS) SLEEP DISORDERED BREATHING (SDB) ASSEMBLY STEERING COMMITTEE HELPING CANADIAN HEALTH CARE PROVIDERS TO OPTIMIZE SDB MANAGEMENT FOR THEIR PATIENTS DURING THE COVID-19 PANDEMIC Najib T. Ayas a , Kristin L. Fraser b , Eleni

2020 Canadian Thoracic Society

3. Sleep Disorder Management

of obstructive sleep apnea syndrome and its outcomes with home portable monitoring. Chest. 2009;135(2):330-336. 4. El Shayeb M, Topfer LA, Stafinski T, Pawluk L, Menon D. Diagnostic accuracy of level 3 portable sleep tests versus level 1 polysomnography for sleep-disordered breathing: a systematic review and meta-analysis. CMAJ. 2014;186(1):E25-E51. 5. Kuna ST, Gurubhagavatula I, Maislin G, et al. Noninferiority of functional outcome in ambulatory management of obstructive sleep apnea. Am J Respir Crit Care (...) Multiple Sleep Latency Testing and Maintenance of Wakefulness Testing 14 Coding 14 General Information 14 Clinical Indications 15 References 15 SLEEP DISORDER TREATMENT MANAGEMENT 17 Management of Obstructive Sleep Apnea using Auto-Titrating and Continuous Positive Airway Pressure Devices 17 Coding 17 General Information 17 Clinical Indications 18 References 20 Bi-Level Positive Airway Pressure Devices 22 Coding 22 General Information 22 Clinical Indications 23 References 24 Management of Obstructive

2020 AIM Specialty Health

4. Rehabilitation in the wake of covid-19 - A phoenix from the ashes

, but it is not yet known whether there is a difference in long-term consequences. • The change in the socioeconomic background that is occurring alongside the pandemic. Rehabilitation in the wake of Covid-19 – A phoenix from the ashes – Issue 2 – www.bsrm.org.uk 8 Table 2: Complications in patients recovering from Covid-19 Most frequent Common, but less frequent • Cardiovascular, pulmonary and musculoskeletal deconditioning. • Restrictive lung disease. • Affective disorders: depression, anxiety, post-traumatic (...) stress disorder. • Post intensive care syndrome, including ICU acquired weakness due to critical illness polyneuropathy/myopathy/both. • Other neurological consequences of the virus and critical care, such as encephalopathy, cerebrovascular events and cerebral hypoxia. • Acute confusional state, at least in the early stages of rehabilitation. • Fatigue. • Cognitive impairment. • Thromboembolic disease: o Myocardial infarction o Stroke o Pulmonary embolism • Musculoskeletal pain and discomfort

2020 British Society of Rehabilitation Medicine

5. British Society of Paediatric Gastroenterology, Hepatology and Nutrition (BSPGHAN) Coronavirus (SARS-CoV-2) and COVID-19 in children with Inflammatory Bowel British Society of Paediatric Gastroenterology, Hepatology and Nutrition (BSPGHAN) Coronavirus (SA

British Society of Paediatric Gastroenterology, Hepatology and Nutrition (BSPGHAN) Coronavirus (SARS-CoV-2) and COVID-19 in children with Inflammatory Bowel British Society of Paediatric Gastroenterology, Hepatology and Nutrition (BSPGHAN) Coronavirus (SA 1 IBD Working Group British Society of Paediatric Gastroenterology, Hepatology and Nutrition (BSPGHAN) Coronavirus (SARS-CoV-2) and COVID-19 in children with IBD Position Statement: Management of PIBD during the SARS-CoV-2 pandemic Specific

2020 British Society of Paediatric Gastroenterology Hepatology and Nutrition

6. Pitolisant for Daytime Sleepiness in Patients with Obstructive Sleep Apnea Who Refuse Continuous Positive Airway Pressure Treatment. A Randomized Trial Full Text available with Trip Pro

was the change in the Epworth Sleepiness Scale score. Key secondary endpoints were maintenance of wakefulness assessed on the basis of the Oxford Sleep Resistance test, safety, Clinical Global Impression of severity, patient's global opinion, EuroQol quality-of-life questionnaire, and Pichot fatigue questionnaire. Measurements and Main Results: A total of 268 patients with obstructive sleep apnea (75% male; mean age, 52 yr; apnea-hypopnea index, 49/h; baseline sleepiness score, 15.7) were randomized (200 (...) With Obstructive Sleep Apnea Who Refuse Continuous Positive Airway Pressure Treatment. A Randomized Trial Yves Dauvilliers et al. Am J Respir Crit Care Med . 2020 . Show details Am J Respir Crit Care Med Actions . 2020 May 1;201(9):1135-1145. doi: 10.1164/rccm.201907-1284OC. Authors , , , , , , , , , , , , , , Collaborators HAROSA II Study Group collaborators : , , , , , , , , , , , , , , , , , , , , Affiliations 1 National Reference Center for Narcolepsy, Sleep and Wake Unit, Department of Neurology, Gui-de

2020 EvidenceUpdates

7. Cost-effectiveness of positive airway pressure modalities in obesity hypoventilation syndrome with severe obstructive sleep apnoea

Cost-effectiveness of positive airway pressure modalities in obesity hypoventilation syndrome with severe obstructive sleep apnoea Cost-effectiveness of Positive Airway Pressure Modalities in Obesity Hypoventilation Syndrome With Severe Obstructive Sleep Apnoea - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Welcome to the new PubMed. For legacy PubMed go to . Clipboard, Search History, and several other advanced features (...) management software Create file Cancel Actions Cite Share Permalink Copy Page navigation Thorax Actions . 2020 Mar 26;thoraxjnl-2019-213622. doi: 10.1136/thoraxjnl-2019-213622. Online ahead of print. Cost-effectiveness of Positive Airway Pressure Modalities in Obesity Hypoventilation Syndrome With Severe Obstructive Sleep Apnoea , , , , , , , , , , , , , , , , , , , , , , , Collaborators, Affiliations Expand Collaborators Spanish Sleep Network

2020 EvidenceUpdates

8. Effects of suboptimal adherence of CPAP therapy on symptoms of obstructive sleep apnoea: a randomised, double-blind, controlled trial

Effects of suboptimal adherence of CPAP therapy on symptoms of obstructive sleep apnoea: a randomised, double-blind, controlled trial Effects of Suboptimal Adherence of CPAP Therapy on Symptoms of Obstructive Sleep Apnoea: A Randomised, Double-Blind, Controlled Trial - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Welcome to the new PubMed. For legacy PubMed go to . Clipboard, Search History, and several other advanced (...) citation management software Create file Cancel Actions Cite Share Permalink Copy Page navigation Eur Respir J Actions . 2020 Mar 20;55(3):1901526. doi: 10.1183/13993003.01526-2019. Print 2020 Mar. Effects of Suboptimal Adherence of CPAP Therapy on Symptoms of Obstructive Sleep Apnoea: A Randomised, Double-Blind, Controlled Trial , , , , , , , , Affiliations Expand Affiliations 1 Dept of Pulmonology, University Hospital Zurich, Zurich, Switzerland. 2 Both authors contributed equally. 3 Epidemiology

2020 EvidenceUpdates

9. Treatment for Insomnia and Disrupted Sleep Behavior in Children and Adolescents with Autism Spectrum Disorder

Administration 14 GERD: gastroesophageal reflux disease 15 OSA: obstructive sleep apnea 16 OTC: over the counter 17 RMD: raw mean difference 18 SE: sleep efficiency 19 SOL: sleep onset latency 20 STS: Sound-to-Sleep 21 TST: time to sleep 22 WASO: wake after sleep onset 23 12 1 2 13 ABSTRACT 1 Objective: To review pharmacologic and nonpharmacologic strategies for treating sleep 2 disturbances in children and adolescents with autistic spectrum disorder (ASD) and to develop 3 recommendations for addressing (...) Weighted blankets 22 23 A 2-week crossover trial in children (5–16 years old) with ASD was Class II for actigraphy 1 outcomes (74% of randomized participants included in analysis) and Class III for sleep diary 2 outcomes. 36 Children had a =5-month history of sleep complaints in the absence of obstructive 3 sleep apnea (OSA), night terrors, or other sleep disorders (n=54–67, depending on arm). Sleep 4 onset latency was no shorter during weeks weighted blankets were used than during weeks 5 regular

2020 American Academy of Neurology

10. Lemborexant (Dayvigo) - insomnia

Lemborexant (Dayvigo) - insomnia Drug Approval Package: DAYVIGO DAYVIGO " /> U.S. Department of Health and Human Services Search FDA Submit search Drug Approval Package: DAYVIGO Company: Eisai Inc. Application Number: 212028 Approval Date: 12/20/2019 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. FDA Approval Letter and Labeling (PDF) (PDF) FDA Application Review Files (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) Date created

2020 FDA - Drug Approval Package

11. Staff and associate specialist (SAS) grade handbook

Staff and associate specialist (SAS) grade handbook www.anaesthetists.org The SAS Handbook 4th edition | 20202 Association of Anaesthetists | The SAS Handbook 2020 Back to contents This work is licensed under a Creative Commons Attribution-NonCommercial-No Derivs 4.0 International License CC BY-NC-ND Every effort was made to ensure that the information in this book was accurate at the time of going to press, but articles (particularly those to do with the organisation of training) have (...) a tendency to go out of date, so you are advised to check with the appropriate organisation for the most up-to-date information. This has been designed as an interactive document and accessible links are highlighted in blue. Weblinks were correct as of October 2019. Foreword I am very pleased to introduce the 4th edition of the Association of Anaesthetists SAS Handbook. I hope it will continue to be an invaluable resource for our SAS members, but also other members, clinical directors and managers

2020 Association of Anaesthetists of GB and Ireland

12. Associations Between Sleep Quality, Sleep Architecture and Sleep Disordered Breathing and Memory After Continuous Positive Airway Pressure in Patients with Obstructive Sleep Apnea in the Apnea Positive Pressure Long-term Efficacy Study (APPLES). Full Text available with Trip Pro

Associations Between Sleep Quality, Sleep Architecture and Sleep Disordered Breathing and Memory After Continuous Positive Airway Pressure in Patients with Obstructive Sleep Apnea in the Apnea Positive Pressure Long-term Efficacy Study (APPLES). The role of sleep architecture in consolidation of memory has not been extensively investigated. In this study, the association of continuous positive airway pressure (CPAP) and sleep architecture and quality, and sleep disordered breathing on changes (...) as well as in relationship to changes in sleep architecture, sleep quality and sleep disordered breathing (SDB).Sleep architecture, sleep quality and SDB improved in the CPAP group at 6 months; performance on the Buschke and DSST improved equally in both CPAP and Sham CPAP groups. There also were no significant correlations between changes in the amount or percentage of sleep stages between baseline and the 6 months, and corresponding changes in either the Buschke or the DSST. However, when stratified

2019 Sleep science (Sao Paulo, Brazil) Controlled trial quality: uncertain

13. Melatonin (sleep disorders) - Benefit assessment according to §35a Social Code Book V

? Carolin Weigel Keywords: melatonin, sleep initiation and maintenance disorders, autism spectrum disorder, Smith-Magenis syndrome, child, adolescent, benefit assessment Extract of dossier assessment A19-04 Version 1.0 Melatonin (Insomnia in children and adolescents with ASD and/or SMS) 11 April 2019 Institute for Quality and Efficiency in Health Care (IQWiG) - iii - Table of contents Page List of tables iv List of abbreviations v 2 Benefit assessment 1 2.1 Executive summary of the benefit assessment 1 (...) ”). The dossier was sent to IQWiG on 11 January 2019. Research question The aim of this report was to assess the added benefit of melatonin in comparison with best supportive care (BSC) as appropriate comparator therapy (ACT) for the treatment of insomnia in children and adolescents aged 2 to 18 years with autism spectrum disorder and/or Smith- Magenis syndrome, when sleep hygiene measures were insufficient. This resulted in 1 research question for the present assessment, for which the G-BA specified the ACT

2019 Institute for Quality and Efficiency in Healthcare (IQWiG)

14. Miniscrew-Assisted Rapid Palatal Expansion May Be an Effective Treatment Modality for Adult Patients with Obstructive Sleep Apnea and a Transverse Maxillary Deficiency

patients with obstructive sleep apnea (OSA) and a transverse maxillary deficiency, is miniscrew-assisted rapid palatal expansion (MARPE) an effective treatment option compared to surgically assisted rapid palatal expansion (SARPE)? Clinical Bottom Line For adult patients with obstructive sleep apnea and a transverse maxillary deficiency and who are seeking a non-surgical treatment option, miniscrew-assisted rapid palatal expansion may be an effective treatment modality to improve breathing. However (...) Miniscrew-Assisted Rapid Palatal Expansion May Be an Effective Treatment Modality for Adult Patients with Obstructive Sleep Apnea and a Transverse Maxillary Deficiency UTCAT3413, Found CAT view, CRITICALLY APPRAISED TOPICs University: | | ORAL HEALTH EVIDENCE-BASED PRACTICE PROGRAM View the CAT / Title Miniscrew-Assisted Rapid Palatal Expansion May Be an Effective Treatment Modality for Adult Patients with Obstructive Sleep Apnea and a Transverse Maxillary Deficiency Clinical Question In adult

2019 UTHSCSA Dental School CAT Library

15. Ambulatory Sleep Study for diagnosing obstructive sleep apnoea

Ambulatory Sleep Study for diagnosing obstructive sleep apnoea '); } else { document.write(' '); } ACE | Ambulatory Sleep Study for diagnosing obstructive sleep apnoea Search > > Ambulatory Sleep Study for diagnosing obstructive sleep apnoea - Ambulatory Sleep Study for diagnosing obstructive sleep apnoea Published on 2 May 2019 Guidance Recommendation The Ministry of Health's MTAC has recommended: Ambulatory sleep study or home sleep test (HST) with a type 2 or type 3 device for diagnosing (...) obstructive sleep apnoea (OSA) in adults aged ≥18 years who fulfil both (A) and (B) . High pre-test probability for moderate-severe OSA, where signs and symptoms indicating a high pre-test probability for moderate-severe OSA include: Excessive daytime sleepiness; and At least two of the following three criteria: (i) habitual loud snoring; (ii) witnessed apnoea, gasping, or choking; and (iii) diagnosed hypertension No complicated conditions that include: Awake hypoventilation or high risk of sleep-related

2019 Appropriate Care Guides, Agency for Care Effectiveness (Singapore)

16. Melatonin for Insomnia: A Review of Clinical Effectiveness, Cost-Effectiveness and Guidelines

effects of melatonin on global sleep outcomes, specific sleep outcomes, and outcomes related to functioning and mood, as well as unclear effects on quality of life for adults with primary and comorbid insomnia. Evidence from one systematic review showed no statistical difference between melatonin and placebo for safety outcomes. No evidence-based guidelines or evidence regarding the cost-effectiveness of melatonin for the treatment of insomnia were identified. Files Rapid Response Summary (...) Melatonin for Insomnia: A Review of Clinical Effectiveness, Cost-Effectiveness and Guidelines Melatonin for Insomnia: A Review of Clinical Effectiveness, Cost-Effectiveness and Guidelines | CADTH.ca Find the information you need Melatonin for Insomnia: A Review of Clinical Effectiveness, Cost-Effectiveness and Guidelines Melatonin for Insomnia: A Review of Clinical Effectiveness, Cost-Effectiveness and Guidelines Last updated: February 22, 2019 Project Number: RC1073-000 Product Line: Research

2019 Canadian Agency for Drugs and Technologies in Health - Rapid Review

17. Management of Surgical Patients with Sleep Apnea: Guidelines

Management of Surgical Patients with Sleep Apnea: Guidelines Management of Surgical Patients with Sleep Apnea: Guidelines | CADTH.ca Find the information you need Management of Surgical Patients with Sleep Apnea: Guidelines Management of Surgical Patients with Sleep Apnea: Guidelines Last updated: July 29, 2019 Project Number: RB1369-000 Product Line: Research Type: Devices and Systems Report Type: Summary of Abstracts Result type: Report Question What are the evidence-based guidelines (...) for preoperative management of surgical patients with known or suspected sleep apnea? What are the evidence-based guidelines for post-operative monitoring and management of surgical patients with known or suspected sleep apnea? Key Message Two evidence-based guidelines were identified regarding preoperative management of surgical patients with known or suspected sleep apnea while no relevant guidelines were identified regarding post-operative management of surgical patients with suspected or known sleep apnea

2019 Canadian Agency for Drugs and Technologies in Health - Rapid Review

18. Benzodiazepines for the Treatment of Adults with Mental Health Conditions or Sleep Disorders Guidelines

Benzodiazepines for the Treatment of Adults with Mental Health Conditions or Sleep Disorders Guidelines Benzodiazepines for the Treatment of Adults with Mental Health Conditions or Sleep Disorders Guidelines | CADTH.ca Find the information you need Benzodiazepines for the Treatment of Adults with Mental Health Conditions or Sleep Disorders Guidelines Benzodiazepines for the Treatment of Adults with Mental Health Conditions or Sleep Disorders Guidelines Last updated: August 27, 2019 Project (...) Number: RB1375-000 Product Line: Research Type: Drug Report Type: Summary of Abstracts Result type: Report Question What are the evidence-based guidelines regarding the use of benzodiazepines and benzodiazepine-related drugs for the treatment of adults with mental health conditions or sleep disorders? Key Message Nine evidence-based guidelines were identified regarding the use of benzodiazepines and benzodiazepine-related drugs for the treatment of adults with mental health conditions or sleep

2019 Canadian Agency for Drugs and Technologies in Health - Rapid Review

19. The role of CPAP treatment in elderly patients with moderate obstructive sleep apnoea: a multicentre randomised controlled trial (Abstract)

The role of CPAP treatment in elderly patients with moderate obstructive sleep apnoea: a multicentre randomised controlled trial The efficacy of continuous positive airway pressure (CPAP) treatment in elderly patients with nonsevere obstructive sleep apnoea (OSA) is controversial. The objective of this study was to assess the effect of CPAP treatment in elderly patients with moderate OSA in terms of clinical, quality-of-life and neurocognitive measures.This was an open-label, randomised (...) , multicentre clinical trial in 145 elderly patients (≥70 years old) with confirmed moderate OSA (apnoea-hypopnoea index 15-29.9 events·h-1) randomised to receive CPAP (n=73) or no CPAP (n=72) for 3 months. The primary end-point was the Epworth Sleepiness Scale (ESS) score, and the secondary end-points included quality of life (Quebec Sleep Questionnaire (QSQ) domain scores), sleep-related symptoms, presence of anxiety/depression, office-based blood pressure measurements and some neurocognitive tests

2019 EvidenceUpdates

20. Melatonin (Slenyto) - Treatment of insomnia in children and adolescents aged 2 to 18 years with autism spectrum disorder and / or Smith-Magenis syndrome

as follows: ADVICE: following a full submission melatonin prolonged-release (Slenyto ® ) is not recommended for use within NHSScotland. Indication under review: Treatment of insomnia in children and adolescents aged 2 to 18 years with autism spectrum disorder and / or Smith-Magenis syndrome, where sleep hygiene measures have been insufficient. Melatonin prolonged-release (Slenyto ® ), compared with placebo, increased total sleep time and sleep onset latency in children aged 2 to 17.5 years with sleep (...) problems and autism spectrum disorder and / or Smith-Magenis syndrome who had an insufficient response to sleep hygiene measures. The submitting company’s justification of the treatment’s cost in relation to its health benefits was not sufficient and in addition the company did not present a sufficiently robust clinical and economic analysis to gain acceptance by SMC. Chairman Scottish Medicines Consortium www.scottishmedicines.org.uk 2 Indication Treatment of insomnia in children and adolescents aged

2019 Scottish Medicines Consortium